Get the Stockscreener App
21.25
1.80%
-0.39
Dbv Technologies Adr stock is traded at $21.25, with a volume of 193.18K.
It is down -1.80% in the last 24 hours and up +3.51% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$21.64
Open:
$21.95
24h Volume:
193.18K
Relative Volume:
0.60
Market Cap:
$1.26B
Revenue:
-
Net Income/Loss:
$-147.32M
P/E Ratio:
-4.0297
EPS:
-5.2733
Net Cash Flow:
$-122.10M
1W Performance:
-1.21%
1M Performance:
+3.51%
6M Performance:
+33.48%
1Y Performance:
+189.12%
1-Day Range:
$21.07
$21.95
1-Week Range:
$20.35
$23.04
52-Week Range:
$7.26
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
21.25 | 1.28B | 0 | -147.32M | -122.10M | -5.2733 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Guggenheim | Buy |
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Goldman Sachs Keeps Their Sell Rating on DBV Technologies SA – American (DBVT) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV technologies S.A. (ADR) (DBV1.SG) Stock Forum & Discussion - Yahoo! Finance Canada
DBV technologies S.A. (ADR) (DBV1.SG) Stock Major Holders - Yahoo! Finance Canada
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Friday - Defense World
DBV technologies S.A. (ADR) (DBV1.SG) company profile and facts - Yahoo Finance UK
Guggenheim Reiterates “Buy” Rating for DBV Technologies (NASDAQ:DBVT) - Defense World
Alphabet To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
DBV Technologies Reports Full Year 2025 Financial Results and Business Update - The Manila Times
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document - The Manila Times
DBV Technologies (NASDAQ: DBVT) deepens 2025 loss but funds runway into 2027 - Stock Titan
DBV files annual report in the US and France, including buyback plan - Stock Titan
Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - The Manila Times
DLD Asset Management LP Makes New $250,000 Investment in DBV Technologies S.A. $DBVT - Defense World
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
DBV Technologies to Participate in Upcoming March Investor Conferences - The Manila Times
Biotech DBV Technologies lines up back-to-back March investor events - Stock Titan
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 - ChartMill
Guggenheim Sticks to Their Buy Rating for DBV Technologies SA – American (DBVT) - The Globe and Mail
DBV Technologies stock surges on new peanut patch trial data - Investing.com
Phase 3 VITESSE data highlighted by DBV Technologies (NASDAQ: DBVT) - Stock Titan
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies Highlights Additional Data from Successful - GlobeNewswire
DBV Technologies (DBVT) Projected to Post Earnings on Thursday - Defense World
European ADRs Were Flat As Biotech Names Took The Lead - Finimize
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
DBV Technologies launches $150M ATM offering - MSN
BioImpact LLC reports 9.99% DBV Technologies (DBVT) stake via shares and warrants - Stock Titan
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - MSN
DBV Technologies to Participate in Biotech Summit - Intellectia AI
DBV Technologies to Present VIASKIN® Data at AAAAI 2026 - Intellectia AI
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies S.A. - Via Ritzau
Peanut allergy patch data in young children to get spotlight at AAAAI 2026 - Stock Titan
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit - markets.businessinsider.com
Biotech summit to feature DBV Technologies CEO fireside chat - Stock Titan
DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
European ADRs Slip As Winners And Losers Split By Region - Finimize
European ADRs Inched Higher As GSK And Telefonica Jumped - Finimize
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '25 |
Sale |
2.22 |
464 |
1,030 |
109,649 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):